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Abstract: 
Nuclear factor E2-related factor 2 (Nrf2) is a critical regulator of cytoprotective gene expression. 
However, the role of this transcription factor in myocardiac cytoprotection against oxidative and 
electrophilic stress remains unknown. This study was undertaken to investigate if Nrf2 signaling 
could control the constitutive and inducible expression of antioxidants and phase 2 enzymes in 
primary cardiomyocytes as well as the susceptibility of these cells to oxidative and electrophilic 
injury. The basal expression of a series of antioxidants and phase 2 enzymes was significantly 
lower in cardiomyocytes from Nrf2−/− mice than those from wild-type littermates. Incubation of 
wild-type cardiomyocytes with 3H-1,2-dithiole-3-thione (D3T) led to significant induction of 
various antioxidants and phase 2 enzymes, including catalase, glutathione, glutathione 
peroxidase (GPx), glutathione reductase, glutathione S-transferase, NAD(P)H:quinone 
oxidoreductase 1, and heme oxygenase-1. The inducibility of the above cellular defenses 
except GPx by D3T was abolished in Nrf2−/− cardiomyocytes. As compared to wild-type 
cells, Nrf2−/− cardiomyocytes were much more susceptible to cell injury induced by H2O2, 
peroxynitrite, and 4-hydroxy-2-nonenal. Treatment of wild-type cardiomyocytes with D3T, 
which upregulated the cellular defenses, resulted in increased resistance to the above oxidant- 
and electrophile-induced cell injury, whereas D3T treatment of Nrf2−/− cardiomyocytes provided 
no cytoprotection. This study demonstrates that Nrf2 is an important factor in controlling both 
constitutive and inducible expression of a wide spectrum of antioxidants and phase 2 enzymes in 
cardiomyocytes and is responsible for protecting these cells against oxidative and electrophilic 
stress. These findings also implicate Nrf2 as an important signaling molecule for myocardiac 
cytoprotection. 
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Introduction 
It is increasingly recognized that oxidative and electrophilic stress are important mechanisms 
underlying various forms of cardiovascular diseases, including atherosclerosis, myocardial 
ischemia-reperfusion injury, chronic heart failure, as well as drug-induced cardiomyopathy [1–
4]. As such, exogenous compounds with antioxidative properties are extensively applied to the 
intervention of cardiovascular injury [5, 6]. However, the use of exogenous antioxidants, 
including vitamin E, in the intervention of human cardiac disorders has produced disappointing 
results, which might be related to the limited bioavailability and effectiveness in scavenging 
oxidative and electrophilic species, as well as other untoward effects (e.g., prooxidative 
properties) associated with these antioxidant compounds [7–10]. Another strategy for protecting 
against oxidative and electrophilic cardiac cell degeneration may be via chemically mediated 
upregulation of a series of endogenous antioxidants and phase 2 enzymes in cardiomyocytes. 
Such a strategy relies on a better understanding of both the constitutive and inducible expression 
of various cardiac cellular antioxidants and phase 2 enzymes as well as the underlying signaling 
mechanisms. 
Recently, the nuclear factor E2-related factor 2 (Nrf2) is found to be an indispensable 
transcription factor that binds to the antioxidant response element (ARE) in the promoter region 
of a number of cytoprotective genes [11, 12]. However, studies on the expression of a series of 
antioxidants and phase 2 enzymes as well as their molecular regulation by Nrf2 signaling in 
primary cardiomyocytes are lacking. In the present study, using neonatal cardiomyocytes 
from Nrf2-null (Nrf2−/−) mice and wild-type (Nrf2+/+) littermates, we have investigated the 
regulatory role of Nrf2 in constitutive expression as well as inducibility by the chemoprotectant, 
3H-1,2-dithiole-3-thione (D3T) of various antioxidants and phase 2 enzymes, including 
superoxide dismutase (SOD), catalase, reduced glutathione (GSH), glutathione reductase (GR), 
glutathione peroxidase (GPx), glutathione S-transferase (GST), NAD(P)H:quinone 
oxidoreductase 1 (NQO1), and heme oxygenase (HO). This study for the first time has 
comprehensively characterized a series of key antioxidants and phase 2 enzymes in primary 
cardiomyocytes, and demonstrated a crucial role for Nrf2 signaling in regulating both the 
constitutive and D3T-inducible expression of the antioxidative and phase 2 defenses, as well as 
in determining the susceptibility of these cardiomyocytes to cell injury elicited by oxidants and 
electrophilic species. The findings of this study thus demonstrate Nrf2 signaling as an important 
pathway for myocardiac cytoprotection against oxidative and electrophilic stress. 
Methods 
Chemicals and Materials 
D3T (99.8% purity) was the gift from Dr. Mary Tanga at SRI International (Menlo Park, CA) 
and Dr. Linda Brady at National Institute of Mental Health (Bethesda, MD). Dulbecco’s 
modified Eagle’s medium (DMEM), penicillin, streptomycin, fetal bovine serum (FBS), and 
Dulbecco’s phosphate buffered saline (PBS) were purchased from Gibco-Invitrogen (Carlsbad, 
CA). Anti-γ-glutamylcysteine ligase (γGCL) antibody was obtained from Lab Vision (Fremont, 
CA). Anti-GR antibody was obtained from Abcam (Cambridge, MA). Anti-GST-A, -M, and -P 
antibodies were purchased from Alpha Diagnostic (San Antonio, TX). Anti-NQO1 and β-actin 
antibodies were provided by Santa Cruz Biotech (Santa Cruz, CA). All other chemicals and 
agents were purchased from Sigma Chemical (St. Louis, MO). 
Animals and Genotyping 
Breeding pairs of Nrf2+/− (ICR/Sv129) mice were initially obtained from a colony at Tsukuba 
University and maintained in the animal facility at Virginia Tech. Nrf2+/+ and Nrf2−/− mice were 
generated following the breeding procedures described previously ([13]. Purina laboratory 
animal chow and water were available ad libitum. Genotypes (Nrf2+/+, Nrf2−/−, and Nrf2+/−) of 
the animals were determined by polymerase chain reaction (PCR) amplification of genomic 
DNA from tails as described before [13]. All the animal procedures were approved by the 
Virginia Tech Institutional Animal Care and Use Committee. 
Primary Cardiomyocyte Culture 
Neonatal mice at the age of 1–3 days were euthanized via cervical dislocation. The hearts were 
removed aseptically, trimmed of atria and connective tissue, and rinsed extensively with ice-cold 
PBS. The cardiomyocytes were isolated using a Neomyts isolation system for mouse 
cardiomyocytes (Cellutron Life Technology, Baltimore, MD) according to the manufacturer’s 
instruction. Briefly, the cardiac cells were dissociated from intact ventricles upon incubation in a 
tissue digestion solution at 37°C with continuous stirring. The cells released were collected by 
centrifugation at 500g for 1 min. The resulting cell pellets were resuspended in culture medium 
and filtered using a cell strainer of 100 μm size (BD Falcon, Redford, MA). After filtration, the 
cells were cultured in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml 
streptomycin in tissue culture flasks at 37°C for 2 h to remove the residual cardiac fibroblasts. 
The cardiomyocytes in suspension were transferred into tissue culture flasks coated with 
SureCoat (Cellutron), and continuously cultured in DEME supplemented with 10% FBS, 
50 U/ml penicillin, and 50 μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2. 
The cells were fed every 3 days, and used for experiments within 10 days after isolation. The 
purity of cardiomyocytes in culture was above 95%, as determined by incubation with a 
monoclonal anti-α-cardiac muscle actinin antibody, followed by staining with a mouse 
ExtraAvidin peroxidase staining kit (Sigma Chemical). For experiments, D3T dissolved in 
dimethyl sulfoxide (DMSO) was added to cell cultures with a final DMSO concentration of 0.1% 
(v/v). Control groups received equal amounts of DMSO. 
Preparation of Cell Extract 
Cardiomyocytes were collected and resuspended in ice-cold 50 mM potassium phosphate buffer, 
pH 7.4, containing 2 mM EDTA and 0.1% Triton X-100. The cells were sonicated, followed by 
centrifugation at 13,000g for 10 min at 4°C. The supernatants were collected and the protein 
concentrations were measured using a Bio-Rad protein assay kit (Hercules, CA) with bovine 
serum albumin as the standard. 
Assay for SOD Activity 
The SOD activity was measured according to the method of Spitz and Oberley [14] with slight 
modifications, as described before [13]. This assay is based on the inhibition of the superoxide-
mediated reduction of nitroblue tetrazolium to formazan by SOD. The cellular SOD activity was 
calculated using a concurrently run SOD (Sigma Chemical) standard curve, and expressed as 
units per mg of cellular protein. 
Assay for Catalase Activity 
The catalase activity was measured using the method described by Aebi [15]. In brief, to a quartz 
cuvette, 0.41 ml of 50 mM potassium phosphate buffer (pH 7.0) and 10 μl of sample were added. 
The reaction was initiated by adding 0.18 ml of 30 mM H2O2 (Sigma Chemical). The 
decomposition of H2O2 was monitored at 240 nm, 25°C for 2 min. The cellular catalase activity 
was expressed as μmol of H2O2 consumed per min per mg of cellular protein. 
Assay for GSH Content 
The GSH content was measured by the o-phthalaldehyde-based fluorescence assay, which is 
specific for the determination of GSH at pH 8.0 [13]. Briefly, 10 μl of the sample was incubated 
with 12.5 μl of 25% metaphosphoric acid, and 37 μl of 0.1 M sodium phosphate buffer 
containing 5 mM EDTA, pH 8.0 at 4°C for 10 min. The samples were cleared of precipitated 
protein by centrifugation at 13,000g for 5 min at 4°C. The resulting supernatant (10 μl) was 
incubated with 0.1 ml of o-phthalaldehyde solution (0.1% in methanol) and 1.89 ml of the above 
phosphate buffer for 15 min at room temperature. Fluorescence intensity was then measured at 
an excitation wavelength of 350 nm and an emission wavelength of 420 nm using a Perkin-
Elmer LS50B fluorometer. The cellular GSH content was calculated using a GSH (Sigma 
Chemical) standard curve, and expressed as nmol of GSH per mg of cellular protein. 
Assay for GR Activity 
The GR activity assay is based on the NADPH consumption coupled with the reduction of 
oxidized form of glutathione (GSSG) to GSH by GR, as described previously [13]. The cellular 
GR activity was calculated using the extinction coefficient of 6.22 mM−1 cm−1, and expressed as 
nmol of NADPH consumed per min per mg of cellular protein. 
Assay for GPx Activity 
The GPx activity was measured by the method of Flohe and Gunzler [16], which is based on the 
formation of GSSG from GPx-catalyzed oxidation of GSH by H2O2, coupled with NADPH 
consumption in the presence of exogenously added GR. The cellular GPx activity was calculated 
using the extinction coefficient of 6.22 mM−1 cm−1, and expressed as nmol of NADPH consumed 
per min per mg of cellular protein. 
Assay for GST Activity 
The GST activity was measured according to the procedures described by Habig et al. [17], using 
1-chloro-2,4-dinitrobenzene (CDNB) as a substrate. The cellular GST activity was calculated 
using the extinction coefficient of 9.6 mM−1 cm−1, and expressed as nmol of CDNB-GSH 
conjugate formed per min per mg of cellular protein. 
Assay for NQO1 Activity 
The NQO1 activity was determined using dichloroindophenol (DCIP) as the two-electron 
acceptor, as described before [13]. The dicumarol-inhibitable cellular NQO1 activity was 
calculated using the extinction coefficient of 21.0 mM−1 cm−1, and expressed as nmol of DCIP 
reduced per min per mg of cellular protein. 
Assay for HO Activity 
The HO activity was measured according to the procedures described by Naughton et al. [18] 
with slight modifications. Briefly, the harvested cells were resuspended in 100 mM potassium 
phosphate buffer, pH 7.4, containing 2 mM MgCl2, and subjected to three cycles of freeze-
thawing and finally sonicated on ice before centrifugation at 18,000g for 10 min at 4°C. As much 
as 100 μl (200 μg protein) of the supernatant was added to 200 μl of reaction mix containing 
0.5 mM NADPH, 2 mM glucose-6-phosphate, 1 U/ml glucose-6-phosphate dehydrogenase, 
0.2 mM hemin, and 1 mg/ml rat liver cytosol (as a source of biliverdin reductase) in 100 mM 
potassium phosphate buffer, pH 7.4, containing 2 mM MgCl2. The reaction was conducted for 
1 h at 37°C in the dark and terminated by addition of 300 μl chloroform. The extracted bilirubin 
was measured by the difference in absorbance between 464 nm and 530 nm (extinction 
coefficient = 40 mM−1 cm−1). The cellular HO activity was expressed as pmol of bilirubin 
formed per h per mg of cellular protein. 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis of mRNA Levels 
Total RNA from cardiomyocytes was extracted using Trizol reagent (Invitrogen, Carlsbad, 
CA). cDNA synthesis and subsequent PCR reaction were performed using Superscript II One-
Step system (Invitrogen), as described before [13]. The sequences for the PCR primers are 
shown in Table 1. PCR products were separated by 1% agarose gel electrophoresis. Gels were 
stained with ethidium bromide and analyzed under ultraviolet light using an Alpha Innotech 
Imaging system (San Leandro, CA). Various amounts of total RNA were used for each of the 
antioxidative and phase 2 genes to demonstrate a linear amplification of the specific mRNA. The 
quantitative capacity of RT-PCR in conjunction with standard curves for detecting mRNA levels 
has previously been characterized by our laboratory and others [19–21].  
Table 1 Oligonucleotide sequences for RT-PCR analysis of gene expression of antioxidants and 
phase 2 enzymes in primary mouse cardiomyocytes 
Enzymes Primers   
Catalase Sense GACATGGTCTGGGACTTCTG 
Antisense GTAGGGACAGTTCACAGGTA 
GCLC Sense GGAGGCTACTTCTGTACTA 
Antisense CGATGGTCAGGTCGATGTCATT 
GR Sense TGCCTGCTCTGGGCCATT 
Antisense CTCCTCTGAAGAGGTAGGAT 
GSTA1 Sense CCGTGCTTCACTACTTCAAT 
Antisense GCATCCATGGGAGGCTTTCT 
GSTM1 Sense CTAGGAAGGGGAGTGCCTAA 
Antisense CAGGCACTTGGGCTCAAACA 
NQO1 Sense CCATTCTGAAAGGCTGGTTTG 
Antisense CTAGCTTTGATCTGGTTGTC 
HO-1 Sense GCCTTGAAGGAGGCCACCAA 
Antisense CCTCAAACAGCTCAATGTTG 
β-Actin Sense GACAACGGCTCCGGCATGT 
Antisense GCAACATAGCACAGCTTCT 
 
Immunoblot Analysis of Antioxidative and Phase 2 Enzymes 
The procedures described before [13] were followed to detect protein expression by immunoblot 
analysis. Briefly, cardiomyocytes were lysed by sonication followed by centrifugation to yield 
the supernatant samples. Equal amounts of protein from each of the samples were resolved 
by SDS-PAGE on 10% gels, and transferred electrophoretically to a nitrocellulose membrane 
(Amersham Biosciences, Piscataway, NJ). The membrane was blocked with 5% non-fat dried 
milk in TTBS buffer at room temperature for 1.5 h. The membrane was then incubated with the 
individual primary antibody overnight at 4°C, followed by incubation with a horseradish 
peroxidase-labeled secondary antibody (Santa Cruz Biotech, Santa Cruz, CA) at room 
temperature for another 1.5 h. The membrane was visualized using an enhanced 
chemiluminescence system (Amersham Biosciences), and the blots were quantified by Gel-Pro 
Analyzer version 4.5 (MediaCybernetics, Silver Spring, MD). 
Assay for Cytotoxicity 
Cytotoxicity was determined by a slightly modified 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium (MTT) reduction assay, as described before [13]. In brief, cardiomyocytes 
were plated into 48-well tissue culture plates. After incubation of the cells with the toxic agents 
in DMEM supplemented with 0.5% FBS at 37°C for 24 h, media were discarded, followed by 
addition to each well of 0.5 ml of fresh medium containing MTT (0.2 mg/ml). The plates were 
incubated at 37°C for another 2 h. Then, media were completely removed followed by addition 
to each well of 0.25 ml of mix of DMSO, isopropanol, and deionized water (1:4:5) to solubilize 
the formazan crystals. The amount of the dissolved formazan was then measured at 570 nm using 
a Beckman DU800 spectrophotometer. 
Statistical Analysis 
All data are expressed as means ± SEM from three separate experiments unless otherwise 
indicated. Differences between mean values of multiple groups were analyzed by one-way 
analysis of variance followed by Student-Newman-Keuls test. Differences between two groups 
were analyzed by Student t-test. Statistical significance was considered at P ≤ 0.05. 
Results 
Effects of Targeted Disruption of Nrf2 on Constitutive Levels/Activities of Antioxidants and 
Phase 2 Enzymes in Cardiomyocytes 
We first examined if targeted disruption of Nrf2 affected the basal levels/activities of 
antioxidants and phase 2 enzymes in cardiomyocytes. As shown in Table 2, the basal 
levels/activities for all of the antioxidants and phase 2 enzymes examined were significantly 
lower in Nrf2−/− cardiomyocytes than in wild-type cells. Notably, targeted disruption of Nrf2 led 
to a 2.3- and 12.5-fold reduction in the basal activities of GST andNQO1, respectively, in 
cardiomyocytes. The levels/activities of other antioxidants and phase 2 enzymes, including SOD, 
catalase, GSH, GR, GPX, and HO, were reduced to various degrees, ranging from 20% to 38% 
decrease, in Nrf2−/− cardiomyocytes as compared to wild-type cells (Table 2).  
Table 2 Basal levels/activities of antioxidants and phase 2 enzymes in primary cardiomyocytes 
derived from Nrf2−/−and wild-type (Nrf2+/+) mice 
Antioxidants/phase 2 proteins Nrf2+/+ Nrf2−/− 
SOD (units/mg protein) 2.4 ± 0.5 1.6 ± 0.4* 
Catalase (μmol/min/mg protein) 13.4 ± 1.7 10.7 ± 0.6* 
GSH (nmol/mg protein) 34.1 ± 0.9 21.1 ± 1.5* 
GPx (nmol/min/mg protein) 54.8 ± 6.5 37.8 ± 5.8* 
GR (nmol/min/mg protein) 56.2 ± 4.6 39.4 ± 2.5* 
GST (nmol/min/mg protein) 70.0 ± 3.5 30.5 ± 3.2* 
NQO1 (nmol/min/mg protein) 85.0 ± 20.4 6.8 ± 0.8* 
HO (pmol/h/mg protein) 288.5 ± 23.2 223.1 ± 32.5* 
 
Data represent means + SEM from three separate experiments. * significantly different 
from Nrf2+/+ cells 
Effects of Targeted Disruption of Nrf2 on Inducibility of SOD and Catalase by D3T in 
Cardiomyocytes 
Incubation of either Nrf2+/+ or Nrf2−/− cardiomyocytes with D3T (25–100 μM) for 24 h did not 
result in any significant changes in SOD activity (Fig. 1a). In contrast, such D3T treatment 
augmented catalase activity in Nrf2+/+ cardiomyocytes; a nearly 2-fold induction of catalase 
activity was observed after treatment of Nrf2+/+cells with 50 μM D3T. However, 100 μM D3T 
treatment did not cause any further induction of catalase activity in Nrf2+/+ cardiomyocytes. The 
inducibility of catalase by D3T was not observed in Nrf2−/−ardiomyocytes; instead, a significant 
decrease in catalase activity was found in the Nrf2−/− cells after treatment with 100 μM D3T 
(Fig. 1b). Immunoblot analysis revealed that D3T treatment of Nrf2+/+cardiomyocytes increased 
the protein level of catalase in a concentration-dependent manner, with the highest induction of 
catalase protein expression observed after treatment with 100 μM D3T. The D3T-mediated 
induction of catalase protein expression was completely abolished in Nrf2−/− cardiomyocytes 
(Fig. 1c and d). 
 
Fig. 1 Effects of D3T treatment on SOD and catalase activities, as well as catalase protein 
expression in Nrf2+/+and Nrf2−/− cardiomyocytes. Cardiomyocytes were incubated with the 
indicated concentrations of D3T for 48 h, followed by measurement of cellular SOD and catalase 
activity, as well as catalase protein expression. Values in panels A and B represent means ± SEM 
from three separate experiments. Immunoblot gel pictures in panel C are representative of two 
separate experiments. Values in panel D represent averages of data from two separate 
experiments, and the data are expressed as relative ratios of density of the catalase protein bands 
after normalization to that of β-actin. *, significantly different from 0 μM D3T 
Effects of Targeted Disruption of Nrf2 on Inducibility of GSH and γ-Glutamylcysteine Ligate 
(γGCL) by D3T in Cardiomyocytes 
Treatment of Nrf2+/+ cardiomyocytes with D3T (25–100 μM) led to a 2–3-fold induction of 
cellular GSH content in a concentration-dependent fashion. A 30% increase in GSH content was 
also observed in Nrf2−/−cardiomyocytes after treatment with 100 μM D3T (Fig. 2a). 
In Nrf2+/+ cardiomyocytes, the protein level of γGCL, the rate-limiting enzyme in GSH 
synthesis, was also remarkably induced by D3T in a concentration-dependent relationship. 
However, no significant induction of γGCL protein by D3T was observed 
in Nrf2−/−cardiomyocytes (Fig. 2b and c). 
 
Fig. 2 Effects of D3T treatment on GSH content and γGCL protein expression 
in Nrf2+/+ and Nrf2−/−cardiomyocytes. Cardiomyocytes were incubated with the indicated 
concentrations of D3T for 48 h, followed by measurement of cellular GSH content, and γGCL 
protein expression. Values in panel A represent means ± SEM from three separate 
experiments. Immunoblot gel pictures in panel B are representative of two separate experiments. 
Values in panel C represent averages of data from two separate experiments, and the data are 
expressed as relative ratios of density of the γGCL protein bands after normalization to that of β-
actin. *, significantly different from 0 μM D3T; #, significantly different from 25 μM D3T; &, 
significantly different from 50 M D3T 
Effects of Targeted Disruption of Nrf2 on Inducibility of GPx and GR by D3T in 
Cardiomyocytes 
Wild-type cardiomyocytes expressed basal activities of GPx and GR, similar to those found in 
most other types of cells. Although the basal activity of GPx in Nrf2−/− cardiomyocytes was 
lower than that in wild-type cells, treatment of either type of cells with D3T led to significant 
induction of GPx activity; an overall 20–30% induction of the enzyme was observed in 
both Nrf2+/+ and Nrf2−/− cardiomyocytes after treatment with D3T (25–100 μM) (Fig. 3a). In 
contrast to GPx, GR in Nrf2+/+ cardiomyocytes was more inducible by D3T; a 30–100% 
induction of GR activity was found after treating these cells with D3T at 25–100 μM. The 
induction of GR by D3T in wild-type cardiomyocytes was dependent on the concentrations of 
D3T. Similarly, immunoblot analysis showed a D3T concentration-dependent induction of GR 
protein expression in Nrf2+/+cardiomyocytes (Fig. 3c and d). In contrast, neither GR activity nor 
its protein level was induced by D3T inNrf2−/− cardiomyocytes. 
 
Fig. 3 Effects of D3T treatment on GPx and GR activities, as well as GR protein expression 
in Nrf2+/+ and Nrf2−/−cardiomyocytes. Cardiomyocytes were incubated with the indicated 
concentrations of D3T for 48 h, followed by measurement of cellular GPx and GR activity, as 
well as GR protein expression. Values in panels A and B represent means ± SEM from three 
separate experiments. Immunoblot gel pictures in panel C are representative of two separate 
experiments. Values in panel D represent averages of data from two separate experiments, and 
the data are expressed as relative ratios of density of the GR protein bands after normalization to 
that of β-actin. *, significantly different from 0 μM D3T; #, significantly different from 25 μM 
D3T 
Effects of Targeted Disruption of Nrf2 on Inducibility of GST and its Major Isozymes by D3T in 
Cardiomyocytes 
GST exists as a family of various isozymes, including GST-A, -M, and -P in mammalial cells 
[22]. As shown in Fig. 4, cardiomyocytes expressed constitutively a measurable total GST 
activity as well as the three major isozyme proteins. The total GST activity 
in Nrf2+/+ cardiomyocytes was highly inducible by D3T in a concentration-dependent manner. 
The induction of GST activity was completely lost in Nrf2−/−cardiomyocytes (Fig. 4a). The basal 
protein levels of GST-A and -M, but not -P, were also significantly lower 
in Nrf2−/− cardiomyocytes than in wild-type cells. Similar to the D3T-inducibility of total GST 
activity in Nrf2+/+cardiomyocytes, the protein levels of GST-A and -M in these cells were also 
highly inducible by D3T in a concentration-dependent relationship. Targeted disruption 
of Nrf2 led to a complete abolishment of the D3T inducibility of the total GST activity as well as 
the protein expression of the A and M isozymes (Fig. 4b–d). 
Both Nrf2+/+ and Nrf2−/− cardiomyocytes showed a similar basal level of GST-P protein. The 
protein level of this GST isozyme was not altered by D3T treatment in 
either Nrf2+/+ or Nrf2−/− cardiomyocytes (Fig. 4e). 
 
Fig. 4 Effects of D3T treatment on total GST activity and the protein expression of GST-A, 
GST-M, and GST-P in Nrf2+/+ and Nrf2−/− cardiomyocytes. Cardiomyocytes were incubated with 
the indicated concentrations of D3T for 48 h, followed by measurement of total cellular GST 
activity, as well as the protein expression of GST-A, -M, and -P. Values in panel A represent 
means ± SEM from three separate experiments. Immunoblot gel pictures in panel B are 
representative of two separate experiments. Values in panels C-E represent averages of data from 
two separate experiments, and the data are expressed as relative ratios of density of the 
respective GST isozyme protein bands after normalization to that of β-actin. *, significantly 
different from 0 μM D3T; #, significantly different from 25 μM D3T; &, significantly different 
from 50 μM D3T 
Effects of Targeted Disruption of Nrf2 on Inducibility of NQO1 by D3T in Cardiomyocytes 
NQO1 is probably the most inducible phase 2 enzyme in mammalian cells. As shown in Fig. 5, 
incubation of Nrf2+/+ cardiomyocytes with D3T (25–100 μM) resulted in a remarkable 4–11-fold 
induction of NQO1 activity as well as the protein expression of this phase 2 enzyme. Targeted 
disruption of Nrf2 in cardiomyocytes not only led to a dramatic reduction of the basal activity 
of NQO1 (Table 2), also a complete abolishment of its inducibility by D3T (Fig. 5). 
 
Fig. 5 Effects of D3T treatment on NQO1 activity and protein expression 
in Nrf2+/+ and Nrf2−/− cardiomyocytes. Cardiomyocytes were incubated with the indicated 
concentrations of D3T for 48 h, followed by measurement of cellular NQO1 activity and protein 
expression. Values in panel A represent means ± SEM from three separate 
experiments. Immunoblot gel pictures in panel B are representative of two separate experiments. 
Values in panel C represent averages of data from two separate experiments, and the data are 
expressed as relative ratios of density of the NQO1 protein bands after normalization to that of β-
actin. *, significantly different from 0 μM D3T; #, significantly different from 25 μM D3T; &, 
significantly different from 50 μM D3T 
Effects of Targeted Disruption of Nrf2 on Inducibility of HO by D3T in Cardiomyocytes 
HO exists in two major isoforms, HO-1 and HO-2, with HO-1 being inducible under various 
stress and inflammatory conditions [23, 24]. We observed that treatment of wild-type 
cardiomyocytes with D3T caused a concentration-dependent increase in the activity of HO, as 
determined by metabolism of heme to eventually form bilirubin. An 80% increase in HO activity 
was found in wild-type cardiomyocytes after treatment with 100 μM D3T. Induction of HO 
activity by D3T was not observed in Nrf2−/− cardiomyocytes (Fig. 6a). Immunoblot assay 
revealed that the basal protein level of HO-1 was also reduced in Nrf2−/−cardiomyocytes as 
compared to wild-type cells. The protein level of HO-1 in Nrf2+/+ cardiomyocytes was 
remarkably increased by D3T treatment; a 70, 100, and 120% increase of HO-1 protein 
expression was observed after treatment of the Nrf2+/+ cells with 25, 50, and 100 μM D3T, 
respectively (Fig. 6b and c). 
 
Fig. 6 Effects of D3T treatment on HO activity and protein expression of HO-1 
in Nrf2+/+ and Nrf2−/−cardiomyocytes. Cardiomyocytes were incubated with the indicated 
concentrations of D3T for 48 h, followed by measurement of cellular HO activity and protein 
expression of HO-1. Values in panel A represent means ± SEM from three separate 
experiments. Immunoblot gel pictures in panel B are representative of two separate experiments. 
Values in panel C represent averages of data from two separate experiments, and the data are 
expressed as relative ratios of density of the HO-1 protein bands after normalization to that of β-
actin. *, significantly different from 0 μM D3T; #, significantly different from 25 μM D3T 
Effects of Targeted Disruption of Nrf2 on Inducibility by D3T of mRNA Levels for Various 
Antioxidative and Phase 2 Enzyme Genes in Cardiomyocytes 
Since D3T-mediated induction of catalase, GSH/γGCL, GR, GST-A, GST-M, NQO1, and 
HO/HO-1 was dependent on the status of Nrf2 (Figs. 1–6), we next examined the effects of 
targeted disruption of Nrf2 on D3T-inducible expression of mRNA for the above antioxidative 
and phase 2 enzymes. As shown in Fig. 7, D3T treatment led to significant time-dependent 
increases in the levels of mRNA for catalase, γGCL catalytic subunit (GCLC), GR, GST-A1, 
GST-M1, NQO1, and HO-1 in wild-type, but not Nrf2−/−cardiomyocytes. Notably, the basal 
levels of mRNA for GCLC, GST-A1, and NQO1 were also reduced inNrf2−/− cardiomyocytes as 
compared to wild-type cells. Although the basal activities and/or protein expression of catalase, 
GR, GST-M, HO/HO-1 were reduced in Nrf2−/− cardiomyocytes, the basal mRNA levels for 
catalase, GR, GST-M1, and HO-1 were not altered by targeted disruption of Nrf2 (Fig. 7). 
 
Fig. 7 Effects of D3T treatment on mRNA expression of various antioxidative and phase 2 genes 
in Nrf2+/+ andNrf2−/− cardiomyocytes. Cardiomyocytes were incubated with 100 μM D3T for the 
indicated time points, followed by detection of cellular mRNA levels for the indicated 
genes. RT-PCR gel pictures in panel A are representative of two separate experiments. Values in 
panel B represent averages of data from two separate experiments, and the data are expressed as 
relative ratios of density of the gel DNA bands for the respective genes after normalization to 
that of β-actin 
Effects of Targeted Disruption of Nrf2 on Susceptibility of Cardiomyocytes to Oxidative and 
Electrophilic Injury as well as the Myocardiac Cytoprotective Effects of D3T 
H2O2 is one of the most commonly encountered reactive oxygen in causing oxidative biological 
damage, including myocardiac cell injury. As shown in Fig. 8a, Nrf2−/− cardiomyocytes showed 
increased sensitivity to H2O2-induced cell injury, as compared to wild-type cells. Pretreatment of 
wild-type cardiomyocytes with D3T afforded a marked cytoprotection against H2O2-medicated 
cell injury; the cytoprotection was remarkable at all of the toxic concentrations of H2O2 used 
(100, 150, 200, and 250 μM). However, D3T pretreatment under the same conditions led to no 
significant cytoprotection against H2O2-mediated cell injury in Nrf2−/−cardiomyocytes. Exposure 
of either Nrf2+/+ or Nrf2−/− cardiomyocytes to 200 μM H2O2 also caused significant changes in 
cell morphology, as indicated by extensive cell shrinkage, loss of cell processes, and presence of 
cell debris (Fig. 9). D3T pretreatment of the wild-type cardiomyocytes prevented the above cell 
morphological changes. However, the same D3T pretreatment of Nrf2−/− cardiomyocytes 
afforded no protection against H2O2-induced morphological damage (Fig. 9). As compared to 
wild-type cells, Nrf2−/−cardiomyocytes also exhibited increased susceptibility to cell injury 
induced by various concentrations of SIN-1, a generator of peroxynitrite, which is a potent 
oxidant in biological systems [25] (Fig. 8b). Pretreatment of wild-type cardiomyocytes with D3T 
afforded a dramatic cytoprotection against SIN-1-induced cell injury. Notably, a remarkable 
cytoprotection by D3T pretreatment was seen at all of the four toxic concentrations (400, 600, 
800, and 1,000 μM) of SIN-1. In contrast, pretreatment of Nrf2−/− cardiomyocytes with the same 
concentration of D3T led to no cytoprotection against SIN-1-induced cell injury (Fig. 8b). As 
shown in Fig. 9, the cell morphological damage (extensive cell shrinkage, loss of cell processes, 
and presence of cell debris) induced by 800 μM SIN-1 was prevented in D3T-
pretreated Nrf2+/+ cardiomyocytes; whereas the above cell morphological damage was not 
protected by D3T pretreatment of the Nrf2−/−cardiomyocytes (Fig. 9). 
 
Fig. 8 Oxidative and electrophilic species-induced cytotoxicity 
in Nrf2+/+ and Nrf2−/− cardiomyocytes, and the cytoprotective effects of D3T pretreatment. 
Cardiomyocytes were incubated with or without 100 μM D3T for 48 h, followed by incubation 
with various concentrations of H2O2, SIN-1, or HNE for another 24 h. After this incubation, 
cytotoxicity was determined by MTT reduction assay. Values represent means ± SEM from three 
separate experiments. *, significantly different from Nrf2(+/+); #, significantly different 
from Nrf2(+/+) 
 
Fig. 9 Oxidative and electrophilic species-induced cell morphological changes 
in Nrf2+/+ and Nrf2−/−cardiomyocytes, and the cytoprotective effects of D3T pretreatment. 
Cardiomyocytes were incubated with or without 100 M D3T for 48 h, followed by incubation 
with 200 μM H2O2, 800 M SIN-1, or 25 μM HNE for another 24 h. After this incubation, cell 
injury was assessed by examining the morphological changes under light microscopy 
To investigate the role of Nrf2 in determining the susceptibility of cardiomyocytes to 
electrophilic stress, we exposed to the cardiomyocytes to 4-hydroxy-2-nonenal (HNE), a potent 
electrophilic species involved in cardiac disorders, including myocardial ischemia-reperfusion 
injury [26, 27]. As shown in Fig. 8c, targeted disruption of Nrf2 dramatically sensitized the 
cardiomyocytes to HNE-induced cell injury. Exposure of wild-type cardiomyocytes to HNE at 
15, 20, 25, and 30 μM also led to significant concentration-dependent decreases in cell viability, 
and the cell injury induced by the above concentrations of HNE was greatly protected by D3T 
pretreatment. However, the same D3T pretreatment of Nrf2−/− cardiomyocytes led to no 
significant cytoprotection against HNE-induced cell injury (Fig. 8c). Similarly, the HNE-induced 
cell morphological changes (extensive cell shrinkage, loss of cell processes, and presence of cell 
debris) were prevented by D3T pretreatment in wild-type, but not Nrf2−/− cardiomyocytes 
(Fig. 9). 
Discussion 
Although it is widely recognized that Nrf2 signaling is indispensable for regulation of a number 
of cytoprotective genes in mammalian tissues, including liver and lung [11, 12, 28], its role in 
controlling either constitutive or inducible expression of a series of antioxidants and phase 2 
enzymes in primary cardiomyocytes remains unknown. A number of studies demonstrate that the 
exact role of Nrf2 signaling in regulating individual antioxidative and phase 2 genes varies 
among different types of cells or tissues [13,28–30]. Thus, it is of importance to investigate the 
involvement of this critical transcriptional activator in regulating myocardiac cellular 
antioxidants and phase 2 enzymes, and in controlling the susceptibility of cardiomyocytes to 
oxidative and electrophilic stress as well as myocardiac cytoprotection by chemoprotectants 
capable of modulating cellular antioxidative and phase 2 enzyme defenses. The results of this 
study demonstrated that the constitutive levels/activities of a series of important antioxidants and 
phase 2 enzymes in primary cardiomyocytes were dependent on the status of Nrf2. While the 
exact underlying mechanisms remain to be elucidated, the reduced levels/activities of 
antioxidants and phase 2 enzymes in Nrf2−/− cardiomyocytes could be due to either a decrease 
in Nrf2-mediated ARE-driven transcriptional activation, or an indirect effect of the altered 
cellular redox state. The later mechanism seemed to be in line with the observation that despite 
the reduced basal activities/protein expression of some of the enzymes, including catalase, GR, 
and HO-1 in Nrf2−/− cardiomyocytes, the mRNA levels for these enzyme genes were not altered 
by the deletion of Nrf2 under the present experimental conditions (Fig. 7). 
Nrf2 signaling controls inducible expression of a large number of cytoprotective genes. 
However, studies on the involvement of Nrf2 in regulating the inducible expression of cellular 
catalase and SOD have yielded inconsistent conclusions. The results of this study showed that 
basal activities of both SOD and catalase were reduced in Nrf2−/− cells (Table 2), treatment of 
cardiomyocytes with D3T caused significant induction of catalase, but not SOD, and the 
induction of catalase by D3T was dependent on Nrf2 (Fig. 1). We previously found that in 
cardiac fibroblasts both SOD and catalase were inducible by D3T in an Nrf2-dependent manner 
[30]. Thus, in different types of cells within even the same tissue Nrf2 appeared to play different 
roles in regulating the inducible expression of SOD. Induction of catalase protein expression by 
D3T in cardiomyocytes showed a concentration-dependency; however the further increased 
catalase protein level in 100 μM D3T treated wild-type cardiomyocytes (Fig. 1c and d) did not 
result in an additional increase in the enzyme activity (Fig. 1b), suggesting that a higher 
concentration (100 μM) of D3T exerted a negative effect on catalase activity. This notion was 
also consistent with the observation that in Nrf2−/− cardiomyocytes, 100 μM D3T caused a 
significant decrease in catalase activity without affecting its protein level (Fig. 1b–d). It remains 
unclear how 100 μM D3T suppressed catalase activity in Nrf2−/− cardiomyocytes. 
In contrast to SOD and catalase, the involvement of Nrf2 signaling in regulating cellular GSH is 
well established [11–13]. The induction of GSH by D3T was dramatically diminished 
in Nrf2−/− cardiomyocytes (Fig. 2), suggesting that Nrf2 was largely responsible for regulating 
D3T-mediated increase of cellular GSH content. D3T-mediated induction of γGCL, the key 
enzyme in GSH biosynthesis, was completely diminished in Nrf2−/− cardiomyocytes, suggesting 
that D3T-mediated elevation of cellular GSH occurred via Nrf2-dependent upregulation of 
γGCL. In this regard, the mRNA level for GCLC, the subunit that determines the catalytic 
activity of the γGCL enzyme complex [31], was also increased by D3T treatment in an Nrf2-
dependent manner (Fig. 7). In Nrf2−/− cardiomyocytes, 100 μM D3T also significantly increased 
cellular GSH content, but not γGCL protein level (Fig. 2). This observation suggested that 
elevation of GSH by D3T in Nrf2 −/−cardiomyocytes might occur via a γGCL-independent 
mechanism. Regardless of the increased level of GSH in 100 μM D3T-
treated Nrf2−/− cardiomyocytes, the complete abolishment of D3T-mediated induction of γGCL 
protein and mRNA expression by targeted disruption of Nrf2 (Figs. 2 and 7) demonstrated 
that Nrf2 signaling was critical for D3T-mediated induction of γGCL, and the subsequent 
elevation of cardiomyocyte GSH content. One notable observation of this study was the similar 
induction of GPx activity by D3T in both Nrf2−/− and wild-type cardiomyocytes 
(Fig. 3). GPx exists as a family of at least six isozymes (GPx1-6), with GPx1 and GPx4 widely 
distributed in mammalian tissues/cells. It is known that the gastrointestinal form of GPx (GPx2) 
is regulated by Nrf2 signaling. In this regard, an ARE is identified in the promoter region of 
GPx2 gene [32]. The similar degree of GPx induction by D3T 
in Nrf2+/+ and Nrf2−/− cardiomyocytes indicated that the inducible expression of the ubiquitous 
forms of GPx (GPx1 and 2) in cardiomyocytes were independent of Nrf2 regulation. Similar to 
what was observed with GSH, D3T also potently induced GR activity as well as its protein 
and mRNA expression in wild-type, but not Nrf2−/− cardiomyocytes (Figs. 3 and7), pointing to a 
critical role for Nrf2 in regulating the inducible expression of GR in cardiomyocytes. The above 
observations were also in line with previous studies, demonstrating that both γGCL and GR 
are Nrf2-regulated antioxidant genes [13, 28–30]. 
Among the various cytoprotective proteins GST and NQO1 are the two most extensively 
investigated Nrf2-regulated phase 2 enzymes [11–13, 28–30]. The constitutive and inducible 
expression of these two phase 2 enzymes and their regulation by Nrf2 pathway in primary 
cardiomyocytes have not been reported in the literature. The dramatic decreases in the basal 
activities of GST and NQO1 in Nrf2−/− cells (Table 2) indicated that Nrf2 signaling was critical 
for regulating the constitutive expression of these two phase 2 enzymes in cardiomyocytes. The 
complete abolishment of the D3T-inducibility of total GST activity in Nrf2−/−cells suggested 
that Nrf2 was also an indispensable factor in regulating not only the basal activity but also the 
inducible expression of GST in cardiomyocytes. GST exists as a family of various isozymes, 
with GST-A, -M, and -P being the three major isozymes in most types of cells [22]. It is 
important to note that the expression of the above GST isoforms, their differential induction by 
chemoprotectants, as well as the role of Nrf2 in their regulation in cardiomyocytes have not been 
investigated. Our results demonstrated that along with induction of the total cellular GST 
activity, D3T treatment also led to significant increases in the protein levels of GST-A and -M, 
as well as the mRNA levels of GST-A1 and -M1 in wild-type, but not Nrf2−/−cardiomyocytes 
(Figs. 4 and 7). Notably, treatment of either wild-type or Nrf2−/− cardiomyocytes with D3T did 
not result in any changes in the protein level of GST-P (Fig. 4). Previous studies also showed 
that GST-P was not readily inducible by chemoprotectants, including D3T in various types of 
cells [13, 33]. It is also possible that different isozymes of GST in cardiomyocytes were 
regulated differently by the Nrf2 pathway. The remarkable induction (up to 11-fold) of NQO1 by 
D3T in Nrf2+/+ cardiomyocytes (Fig. 5) was unexpected. This observation may have important 
implications in cardioprotection in view of the recent observations thatNQO1 is not only capable 
of detoxifying electrophilic quinones, but also acting as an antioxidative enzyme, a scavenger of 
superoxide, as well as a p53-stabilizing protein [34–37]. 
Another important observation of this study was the potent induction of HO/HO-1 by D3T in 
cardiomyocytes that occurred in an Nrf2-dependent relationship (Figs. 6 and 7). HO-1 has been 
recently demonstrated to play a crucial role in defending cells against oxidative and 
inflammatory stress. In this context, HO-1 overexpression is found to be protective against 
various forms of cardiovascular diseases, including atherosclerosis and myocardial ischemia-
reperfusion injury [23, 24, 38, 39]. The significant induction of HO/HO-1 by D3T in 
cardiomyocytes via an Nrf2-dependent mechanism may thus be an important pathway for 
myocardiac cytoprotection against oxidative and inflammatory injury. 
Studies over the last two decades have demonstrated that oxidative and electrophilic stress as 
well as dysregulated inflammation are intimately involved in the pathophysiological processes of 
various cardiac diseases [1–4]. Accordingly, upregulation of endogenous antioxidants and phase 
2 enzymes may represent an effective strategy for myocardiac cytoprotection against oxidative 
and electrophilic injury. To investigate if Nrf2-dependent regulation of endogenous cellular 
antioxidative and phase 2 defenses plays an important part in myocardiac cytoprotection, 
cardiomyocytes were exposed to various oxidative and electrophilic species, including H2O2, 
SIN-1-derived peroxynitrite, and HNE. H2O2 and peroxynitrite are the most encountered 
oxidants in biological systems. Indeed, these oxidative species have been found to be responsible 
for injury of cardiomyocytes in various cardiac disorders, such as myocardial ischemia-
reperfusion injury [1–4]. As expected, cell injury induced by H2O2 or SIN-1-derived 
peroxynitrite was markedly augmented in Nrf2−/− cardiomyocytes, and D3T-treatment of the 
wild-type, but not Nrf2−/−,cardiomyocytes provided a remarkable cytoprotection against these 
oxidant-induced cell injury (Figs. 8 and 9). It is known that detoxification of H2O2 in mammalian 
cells relies on several cellular antioxidants, especially GSH (in the presence of GPx) and 
catalase. GSH in the presence of GPx has also been found to be a major cellular mechanism for 
detoxification of peroxynitrite [40]. In addition, the augmented activity of GR by D3T could also 
contribute to the increased levels of GSH due to its ability to reduce GSSG to GSH. Therefore, 
the reduced constitutive expression of the above antioxidants as well as their inability to be 
upregulated by D3T in Nrf2−/− cardiomyocytes were most likely responsible for the increased 
susceptibility of these cells to the above oxidant-elicited cell injury. The increased resistance of 
the D3T-treated Nrf2+/+cardiomyocytes to oxidative stress may also result partially from the 
potent induction of HO-1 by D3T (Figs. 6 and 7). HO-1 catalyzes the decomposition of heme to 
produce the potent antioxidant, bilirubin and the anti-inflammatory/antioxidative molecule, 
carbon monoxide [23, 24]. Overexpression of HO-1 has been demonstrated extensively to protect 
cells, including cardiomyocytes from oxidative injury [23, 24]. 
In addition to its direct involvement in detoxification of oxidants, GSH is also a cofactor for 
GST, an abundant cellular enzyme primarily involved in the detoxification of electrophilic 
compounds via catalyzing the formation of GSH-electrophile conjugates [22]. Several recent 
studies have demonstrated that GST also plays a critical role in protecting cells from oxidant-
mediated injury through catalyzing the decomposition of lipid hydroperoxides generated from 
oxidative damage of cellular lipid molecules [41, 42]. Accordingly, the marked induction of GST 
by D3T in Nrf2+/+ cardiomyocytes may also contribute partially to the increased resistance of the 
D3T-treated cells to the oxidant-elicited cytotoxicity. 
As mentioned above, NQO1 not only detoxifies electrophilic quinones but also plays a critical 
role in controlling oxidative stress via maintaining high levels of cellular vitamin E and 
ubiquinol, two important antioxidants [34]. This is particularly relevant for the involvement 
of NQO1 in protecting against oxidative myocardiac cell injury in view of the extremely high 
D3T-inducible expression of this phase 2 enzyme in Nrf2+/+ cardiomyocytes (Fig. 5). 
Targeted disruption of Nrf2 augmented the susceptibility of cardiomyocytes to HNE-induced cell 
injury (Figs. 8 and 9). HNE is a potent electrophilic, α, β-unsaturated aldehyde, which is formed 
during lipid peroxidation in biological systems [43]. HNE has been implicated in the 
pathogenesis of various cardiac disorders, including myocardial ischemia-reperfusion injury 
[26, 27]. Although a number of cellular factors have been proposed to participate in metabolism 
of HNE in biological systems, detoxification of HNE heavily relies on cellular GSH system in 
mammalian cells [22, 44]. In this context, due to its high electrophilic property, HNE readily 
reacts with GSH to form a less reactive GSH-conjugate, leading to its detoxification [22]. The 
presence of GST has also been found to promote the conjugation reaction between HNE and 
GSH [22, 45]. Thus, the decreased level/activity of GSH/GST and their inability to be induced 
by D3T would account for the augmented sensitivity of the Nrf2−/− cardiomyocytes to HNE-
induced cell injury and for the failure of D3T treatment to protect these cells from HNE toxicity. 
In summary, the results of the present study demonstrate that Nrf2 is indispensable for the 
regulation of both constitutive and D3T-inducible expression of a series of key antioxidants and 
phase 2 enzymes in mouse primary cardiomyocytes. Nrf2 signaling is also an important 
mechanism in controlling cardiomyocyte susceptibility to cell injury elicited by various oxidative 
and electrophilic species. In view of the crucial involvement of oxidative and electrophilic injury 
of cardiomyocytes in the pathophysiological processes of various cardiac disorders, Nrf2-
dependent coordinated regulation of a series of antioxidants and phase 2 enzymes in these cells is 
of importance in protecting against the pathogenesis underlying cardiac diseases. The results of 
this study implicate Nrf2 signaling pathway as an important mechanism for myocardiac 
cytoprotection. 
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